Vivos Therapeutics Files 8-K: Other Events & Exhibits
Ticker: VVOS · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1716166
| Field | Detail |
|---|---|
| Company | Vivos Therapeutics, Inc. (VVOS) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, corporate-events, filing
TL;DR
Vivos Therapeutics dropped an 8-K on 12/17 detailing 12/16 events - check for updates.
AI Summary
Vivos Therapeutics, Inc. filed an 8-K on December 17, 2025, reporting on events that occurred on December 16, 2025. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items. The company, previously known as Vivos BioTechnologies, Inc., is incorporated in Delaware and headquartered in Littleton, Colorado.
Why It Matters
This 8-K filing signals that Vivos Therapeutics has reported significant corporate events or financial updates to the SEC, which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not inherently present new risks.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Registrant
- Vivos BioTechnologies, Inc. (company) — Former company name
- December 16, 2025 (date) — Date of earliest event reported
- December 17, 2025 (date) — Filing date
- Littleton, Colorado (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Vivos Therapeutics on December 16, 2025?
The provided text does not detail the specific 'Other Events' beyond listing it as an item information category in the 8-K filing.
What financial statements or exhibits are included in this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information category, but the specific contents are not detailed in the provided text.
When was Vivos Therapeutics, Inc. previously known as Vivos BioTechnologies, Inc. and when did the name change occur?
The company was formerly known as Vivos BioTechnologies, Inc., and the date of the name change was September 1, 2017.
What is the principal executive office address for Vivos Therapeutics, Inc.?
The principal executive offices are located at 7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120.
What is the SEC file number and Central Index Key for Vivos Therapeutics, Inc.?
The SEC file number is 001-39796, and the Central Index Key is 0001716166.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-12-16 17:54:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 18KB
- 0001493152-25-028019.txt ( ) — 222KB
- vvos-20251216.xsd (EX-101.SCH) — 3KB
- vvos-20251216_lab.xml (EX-101.LAB) — 33KB
- vvos-20251216_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 7921 Southpark Plaza , Suite 210 Littleton , Colorado 80120 (Address of principal executive offices) (Zip Code) (866) 908-4867 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Information. On December 16, 2025, Vivos Therapeutics, Inc. (the "Company") issued a press release announcing the grand opening of its latest sleep testing and treatment center near Detroit in Auburn Hills, Michigan. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 16, 2025 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIVOS THERAPEUTICS, INC. Dated: December 16, 2025 By: /s/ Bradford Amman Name: Bradford Amman Title: Chief Financial Officer